IPOs

Paul Capital Healthcare to Participate in Panel on Non-Traditional Forms of Financing

...otechnology Industry Organization International Convention, will be held at the Georgia World Congress Center in Atlanta. Relevant at a time when ipos are hard to execute and equity valuations uncertain, this panel will explore various models for obtaining capital for product development other than t...

Medical Devices Get Most Funding in Slow Stretch for VC: Mid-Year Results from Healthcare Corporate Finance News

...ces," remarked Gretchen S. Swanson, Editor of Healthcare Corporate Finance News. "In addition, the current lack of demand for venture-backed ipos is giving investors and entrepreneurs a reason to focus on intensifying efficiency and consider alternate strategic options for accessing capital.&quo...

Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Council's Ninth Annual MASS Opportunities Investment Conference

... "Following last year's MASS Opps, the private presenting companies announced $198 million in new venture capital fundraising. Two companies announced ipos totaling more than $107 million, and twelve alliances and partnerships were formed including a $1 billion licensing deal," said Massachusetts Biotechn...

Biotech Finishes on a High in August, Burrill Report Says

...priority review status by the FDA, the drug is on the fast track for regulatory clearance." Biotech IPO review It was another slow month for biotech ipos with only two companies getting their offerings completed. WuXi PharmaTech, a China-based pharmaceutical and biotechnology research and development ou...

Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007

...Newswire/ -- Gerresheimer AG has been listed in the Prime Standard of the Frankfurter Stock exchange since June 11, 2007, following one of the largest ipos of the year, with a total issue volume of more than 900 million euros. Gerresheimer stock will be included in the SDAX index of Deutsche Borse, Frankf...

IPOs in Biological Technology

Biotech IPOs bring in encouraging sums

CHICAGO In last weeks column, I raised the premise that in the early years of biotech it wasnt about making money but about providing radically new solutions to health care. Theres a thread drawn to the early years of rock n roll where it was also not about making money but about expressing ...

Wisconsin IPOs are a harbinger of growing tech economy

Madison, Wis. - For the second time this year, a tech-based company in Wisconsin has announced plans to offer its stock for sale to the public. Called an initial public offering, this kind of business activity is not only important to the companies and investors who are directly involved, but t...

Global Financial Crisis Making Biotech Business Model Unsustainable, According to Ernst & Young

...% in 2008, led by strong growth in Australia. In Australia, public-equity funding fell to levels not seen since 2002. There were a handful of ipos in Japan and China and strong private-equity funding growth in India. About Ernst & Young's Global Biotechnology Center ...

InformexUSA 2009 Opens to Strong Attendance

...et holds promise despite the economic climate. "We've all seen the reports that say that 30% of the biopharma industry has only 6 months of cash, that ipos are down 97% and that venture financing is down 30%," said Langer. "Beneath the surface, a close look at what is actually happening in the market reve...

TechMandA.com Marketplace Streamlines M&A Process for Technology Businesses

...access to potential buyers and sellers of technology business, with reduced effort and expense. "In a market which has seen four technology ipos all year, technology businesses are infinitely more likely to exit through a sale than an IPO. With our new free listing marketplace, TechMandA.com i...

Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets

...3 initial public offerings (IPOs) were successfully completed in 2007, only three were completed in the first half of 2008. Total 2007 funding through ipos rose to US$1.1 billion, a 54% increase over 2006. The average valuation at the time of the IPO swelled to US$405 million, a 94% increase over 2006. ...

TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm

...Sciences team builds on the expertise, experience, international approach and demonstrated success in more than 100 previous investments and almost 40 ipos from our biotechnology and pharmaceutical portfolio of companies. The team combines long-standing international investment experience with pharmaceuti...

Biotech Avoids Fall Out From Tough Quarter for Capital Markets

...his is reflected in the fact that the Amex Pharmaceutical Index closed the quarter down 12% at 295.23, its lowest total since October 2004." Biotech ipos on hold The prevailing tough economic environment also took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and Archemix can...

Antibody Engineering Company F-Star Buys Back Royalty Obligations

...ience team builds on the expertise, experience, international approach and demonstrated success in more than 100 previous investments and more than 30 ipos from its biotechnology and pharmaceutical portfolio of companies. For more information, visit http://www.tvm-capital.com Company contact: ...

Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities

...ompanies in the life sciences sector across the full spectrum of transactions - M&A, divestments, corporate partnering/licensing (inward and outward), ipos and financings. Prior to Marquant, Joy's positions included: Vice President, Business Development at Nabi Biopharmaceuticals; Vice President, Business...